Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Biogen (BIIB) with a Peer Perform rating. With a legacy portfolio that ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far ...

Industry leaders in health and science converged in downtown Raleigh Thursday to highlight the area’s latest advancements in ...

In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

State Treasurer Deb Goldberg, Commissioner Jeffrey McCue of MA Department of Transitional Assistance, Suffolk County District Attorney Kevin Hayden, as well as several other state and local officials ...